Stockreport

Affimed Announces Collaboration with Genentech to Develop Novel NK Cell Engager-based Immunotherapeutics for Multiple Cancer Targets

Affimed N.V.  (AFMD) 
Last affimed n.v. earnings: 11/19 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: affimed.com/investor-relations.php
PDF Affimed will receive $96 million upfront and committed funding and is eligible for up to an additional $5.0 billion including milestone payments, and royalties on sales [Read more]